Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
French Innovative Leukemia Organisation
With
Janssen, LP
Mundipharma Pte Ltd.
OBJECTIVES:
Primary
* Evaluate the efficacy of rituximab, bortezomib, doxorubicin hydrochloride, dexamethasone, and chlorambucil as first-line therapy in patients with stage II-IV mantle cell lymphoma.
Secondary
* Determine the complete response rate in these patients.
* Determine the efficacy, in terms of complete and overall response, by F18 fludeoxyglucose scan.
* Determine overall, disease-free, and event-free survival of these patients.
* Assess tolerability of this regimen in these patients.
* Evaluate the impact of factors, described in previous protocols, on response to therapy and survival.
* Assess the impact of residual disease in cerebrospinal fluid on survival.
OUTLINE: This is a multicenter study.
Patients receive rituximab IV on day 1 (days 1 and 8 of the first course only); bortezomib IV on days 1, 4, 8, and 11; doxorubicin hydrochloride IV continuously over 24 hours on days 1-4; dexamethasone IV on days 1-4; and oral chlorambucil on days 20-29. Treatment repeats every 5 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients who achieve at least 50% response receive 2 additional courses of therapy.
Age
65–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of mantle cell lymphoma
* Stage II-IV disease
No neuromeningeal disease
PATIENT CHARACTERISTICS:
WHO performance status 0-2
No prior cancer except for carcinoma in situ of the cervix or basal cell skin cancer
LVEF \> 50%
HIV-negative
Hepatitis B- and C-negative
No hepatocellular, renal, or bone marrow insufficiency unrelated to lymphoma